【摘要】 目的 探讨t(8；21)急性髓系白血病(acute myeloid leukemia，AML)的临床特点及预后，提高对t(8；21)AML的认识。 方法 2010年5月收治1例t(8；21)AML患者，对其临床资料并复习相关文献进行分析。患者因乏力、皮下瘀斑入院，查体发现患者有胸骨压痛，脾肋下3 cm触及，血常规:白细胞80.37×109/L，异常细胞 23%，取患者骨髓液行形态学、流式细胞术检测及染色体核型检测。 结果 患者诊断为急性粒细胞白血病部分分化型(AML-M2b)，AML1/ETO融合基因阳性，染色体核型分析t(8；21)(q22；q22)。 结论 t(8；21)AML是一类较为特殊的急性髓系白血病，在诊断时需寻找疾病的预后因素并进行分层，实施个体化治疗。【Abstract】 Objective To obsrve the clinical features and prognosis of acute myeloid leukemia (AML) with t(8;21). Methods The clinical data of one patient with t (8; 21) AML diagnosed in May 2010 was retrospectively analyzed. The chief complaints of the patient were malaise and ecchymosis. The physical examinations revealed sternum pain and splenomegaly; blood routine examination showed that the peripheral WBC count was 80.37×109/L, and the abnormal cells were 23%. Bone marrow samples were collected to perform the morphologic test, flow cytometry analysis and chromosome analysis. Results The patient was diagnosed as AML with maturation (AML-M2) with positive AML1/ETO fusion gene and translocation (8; 21) (q22; q22). Conclusion AML with t (8; 21) is different with other types of AML; patients with AML with t (8; 21) need individualized treatment.
ObjectiveTo systematically review the correlation between DNMT3a mutation and peripheral blood cell count on the time of diagnosis for adult primary acute myeloid leukemia (AML). MethodsLiterature search in the databases such as PubMed, ScienceDirect, EBSCO, Web of Science, CNKI, VIP and WanFang Data was performed to collect the case-control studies about the correlation between the DNMT3a mutations and adult AML up to December 2012. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the methodological quality of the included studies, and then RevMan 5.0 software was conducting for metaanalysis. ResultsA total of 10 studies involving 2 704 patients were included. The results of meta-analyses showed that:the levels of peripheral blood WBC, HGB and PLT of the DNMT3a-mutated group were significantly higher than those of the DNMT3a-wildtype group for the initial visit of adult primary AML patients (all P values < 0.05). ConclusionThe peripheral blood cell counts of the DNMT3a-mutated group are higher than those of the DNMT3a-wildtype group for the initial visit of adult primary AML patients, indicating DNMT3a mutation might contribute to promote cell proliferation, and this helps us better understand the role of DNMT3a mutation in the development of AML.
Objective To systematically review the health economic evaluation studies of medicines for the treatment of acute myeloid leukemia (AML). MethodsThe PubMed, EMbase, Cochrane Library, CBM, CNKI, and WanFang Data, as well as the CRD database specifically for health economics were electronically searched from inception to June 2022, and related journals in the field of health economics and the websites of HTA institutions in various countries were manually searched. The quality of the studies was assessed using the CHEERS checklist. The basic characteristics of health economics evaluation publications were summarized, the quality of model structures and methodologies was assessed and economic evaluation results were compared among different treatments. Results A total of 17 studies were included, and cost-effectiveness analyses were conducted from the perspectives of the health system, patients, the whole society, and medical insurance payers. The economic evaluation models were relatively unified, but there were differences in methods and results reporting, and the quality needed to be improved. The research objects were mainly the comparison of hypomethylating agents, targeted medicine and traditional chemotherapy regimens, as well as the comparison of different chemotherapy combinations and different drug dosages. Conclusion Real-world studies are mainly focused on traditional chemotherapy regimens, and model-based health economic evaluations, such as Markov models, are more frequently applied to newly developed targeted drugs and demethylation drugs. Among all treatments, the chemotherapy regimens including cytarabine, midostaurin, and decitabine are found to be more cost-effective.